Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant bevacizumab plus TAC versus TAC with placebo in stage II–III breast cancer
2005-000104-13Phase 2Completed
- Sponsor
- TRIO
- Start
- Jun 2005
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in breast cancer comparing Bevacizumab arm with Placebo arm (2 arms). Primary endpoints: Safety and toxicity of TAC plus bevacizumab and Rate of congestive heart failure (CHF). Started Jun 2005; status: completed.
02
Drugs
bevacizumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2005-000104-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-000104-13.